All operations are carried out in accordance with cGMP standards and in full compliance with the regulatory requirements of the Swiss (Swissmedic), European (EMA) and United States (US-FDA) health authorities.
Micro-Sphere also has extensive demonstrated expertise in the field of high-potency active pharmaceutical ingredients (HPAIs), particularly with dry powders for inhalation and water-insoluble molecules for nanoemulsion dispersion. However, with its core business being contract manufacturing and development of pharmaceutical products, Micro-Sphere also has development capabilities in cosmetics, nutraceuticals and natural products, as well as medical devices.
Lacto-Sphere® is Micro-Sphere’s proprietary Lactose based on the raw material lactose monohydrate of US origin, thus BSE/TSE free. Lacto-Sphere is developed specifically for respiratory formulations and is produced in two variations: Lacto-Sphere MM3 (average particle size 3 μm) and Lacto-Sphere MM50 (average particle size 50 μm).
Micro-Sphere SA

Micro-Sphere is located in southern Switzerland. Through practical experience gained over the past decade, Micro-Sphere has advanced its know-how in spray drying techniques for almost 100 different active pharmaceutical ingredients (API) used in the pharmaceutical industry today.
Micro-Sphere is located in southern Switzerland. Through practical experience gained over the past decade, Micro-Sphere has advanced its know-how in spray drying techniques for almost 100 different active pharmaceutical ingredients (API) used in the pharmaceutical industry today.
Activities
Main Activity
Development
Co-development
Drug Product CMO
Drug Substance CMO
Drug discovery (Partial)
Drug development
Drug commercialization
Isolates
Analytical Services
Micronization (Partial)
Pre-formulation
Spray-Drying
Other Activities
Therapeutic Areas
Cancer supportive therapy
Cardiology
CNS
Dermatology
Endocrinology/Diabetes
Gastrointestinal
Gynaecology/Women's Health
Infertility
Infectious diseases
Anesthesia
Mental health
Metabolism
Oncology
Ophthalmology
Orthopedics
Pain
Respiratory
Rheumatology
Urology
Other therapeutic areas
Markets
CH
Rest of Europe
USA and Canada
Japan
LATAM
MENA
BRICS
ASEAN
Australia
Other market
Drug Stages
Pre-clinical
Clinical Phase I/Phase III
Phase I - Phase III
Registration (Partial)
Market
Generic Plus (505B2)
Generic
Life cycle management
Drug Product Forms
Inhaler
Injectable
Oral (solid)
Certifications
Swissmedic
FDA
European Medicines Agency
BRC Global Standards
PMDA
Other Certifications